OPPM
VKTX icon

Opus Point Partners Management’s Viking Therapeutics VKTX Stock Holding History

Opus Point Partners Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-48,485
Closed -$402K – 64
2019
Q2 		$402K Hold
48,485
– – 0.59% 43
2019
Q1 		$482K Buy
+48,485
New +$406K 0.65% 37

Other funds holding VKTX

ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Opus Point Partners Management's VKTX Position: Q3 2019 in Review

Opus Point Partners Management sold out of Viking Therapeutics (VKTX) in Q3 2019, closing a stake of 48,485 shares — an estimated $402K sold.

Opus Point Partners Management first reported a position in VKTX in Q1 2019 and held it in 2 quarters. The position peaked at $482K in Q1 2019. 144 funds tracked by Wall St. Rank hold VKTX as of Q3 2019.

  • Opus Point Partners Management reported no remaining Viking Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Opus Point Partners Management sold 48,485 Viking Therapeutics shares in Q3 2019, an estimated $402K.
  • Opus Point Partners Management first reported a position in Viking Therapeutics in Q1 2019 and held it in 2 quarters.
  • Opus Point Partners Management's Viking Therapeutics position peaked at $482K in Q1 2019.
  • 144 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2019.

Based on Opus Point Partners Management's 13F filing for Q3 2019, filed 14 Nov 2019.